Rayno Life Science Portfolio: Seracare (SRLS) Surges 11% on Earnings
SeraCare Reports 40% Increase in Net Income Over Prior Year SeraCare (SRLS) executed six consecutive quarters of successful growth with revenue growth of 13% to $50.4 M for the fiscal year ending SEP 30, compared to revenues of $44.4M year in 2009. Net Income was $6.7M or $0.35/s on a diluted...
Vermillion(VRML):Novel Diagnostic Tests Utilizing Biomarkers
Restructuring Play in Diagnostics at a VC Valuation Vermilion(VRML) technology utilizes a panel of biomarkers integrated with multivariate analysis software to develop disease specific assays. The R&D effort leverages collaborations with institutions such as Stanford, John Hopkins and MD...
Rayno Life Science Portfolio:Gen-Probe(GPRO) Files PMA Application for HPV
Gen-Probe (GPRO,$51.60) announced yesterday that it submitted a Premarket Approval Application(PMA) the the FDA for its APTIMA HPV (human papillomavirus ) assay , a molecular diagnostic test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions....
Cepheid (CPHD) GeneXpert TB Test in India
"A Deadly Misdiagnosis" by Michael Specter An interesting article in the November 15 New Yorker on the Tuberculosis epidemic in India stresses the need for more accurate diagnostic tests and how the Cepheid TB assay can save lives. The author reports on the complexity and economics of India's...
Biomarkers and Blood Screening Tests: GenProbe (GPRO) and Genzyme(GENZ)
Here are some relevant news in areas that we previously covered: Biomarkers Genzyme (GENZ) licensed a lung cancer test under development to Roche and can target a patient's response to their Tarceva cancer drug. The goal is a test for epidermal growth- factor receptor (EGFR) mutations that...